Analysis exploring Medicare formulary changes following the publication of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults found that, although the cholesterol guideline was originally associated with more restrictive formulary coverage of non-statin lipid-lowering medications, many formularies continue to provide unrestrictive coverage. The research letter was published Jan. 9 in the Journal of the American College of Cardiology. The authors explain that although there was an association with increased restrictiveness for non-statin lipid-lowering medications after publication of the guideline, the changes were inconsistent, and many formularies continued to provide high rates of unrestrictive coverage without first requiring use of a statin. Read more on ACC.org.